Welcome to Corporate Drug Safety

On May 7, 2018, Impax Laboratories, Inc. combined with Amneal Pharmaceuticals, Inc. (NYSE:AMRX) to create a dynamic company powered by a robust U.S. generics business and growing branded franchise. Today, we are working to integrate our business into the new Amneal and are excited about our future as one company.

In the meantime, there is no change to our Corporate Drug Safety program, which is dedicated to the management of the benefit risk profile associated with the administration of Impax Laboratories commercial and investigational products to optimize patient safety.

This is accomplished by a pharmacovigilance system consisting of adverse event case management, aggregate data analysis and reporting, medical assessment and signal detection activities, risk management planning and global regulatory reporting capabilities. Impax is committed to compliance with the applicable worldwide regulations. This information helps us better understand drug safety profiles and deliver safe products to patients.